Planning influenza vaccination programs: a cost benefit model

Cost Effectiveness and Resource Allocation

Heather S Kirkham¹  Junjie Zhang¹  Michael S Taitel¹  Ian G Duncan¹ 

[1] Clinical Outcomes & Analytic Services, Walgreens Co., 1415 Lake Cook Rd., MS L444, Deerfield, IL, 60015, USA

关键词: Economic model;    Cost benefit;    Vaccination;    Immunization;    Influenza;   

Others  :  810862
DOI  :  10.1186/1478-7547-10-10

 received in 2011-08-24, accepted in 2012-07-02,  发布年份 2012

【 摘 要 】

Background

Although annual influenza vaccination could decrease the significant economic and humanistic burden of influenza in the United States, immunization rates are below recommended levels, and concerns remain whether immunization programs can be cost beneficial. The research objective was to compare cost benefit of various immunization strategies from employer, employee, and societal perspectives.

Methods

An actuarial model was developed based on the published literature to estimate the costs and benefits of influenza immunization programs. Useful features of the model included customization by population age and risk-level, potential pandemic risk, and projection year. Various immunization strategies were modelled for an average U.S. population of 15,000 persons vaccinated in pharmacies or doctor’s office during the 2011/12 season. The primary outcome measure reported net cost savings per vaccinated (PV) from the perspective of various stakeholders.

Results

Given a typical U.S. population, an influenza immunization program will be cost beneficial for employers when more than 37% of individuals receive vaccine in non-traditional settings such as pharmacies. The baseline scenario, where 50% of persons would be vaccinated in non-traditional settings, estimated net savings of $6 PV. Programs that limited to pharmacy setting ($31 PV) or targeted persons with high-risk comorbidities ($83 PV) or seniors ($107 PV) were found to increase cost benefit. Sensitivity analysis confirmed the scenario-based findings.

Conclusions

Both universal and targeted vaccination programs can be cost beneficial. Proper planning with cost models can help employers and policy makers develop strategies to improve the impact of immunization programs.

【 授权许可】

   
2012 Duncan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB: The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
• [2]Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E: Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50–64 years. Clin Infect Dis 2009, 48:292-298.
• [3]U.S.Department of Health and Human Services: Healthy People 2020. US Department of Health and Human Services, Washington, DC; 2011.
• [4]Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ: Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.
• [5]Monto AS: Seasonal influenza and vaccination coverage. Vaccine 2010, 28(Suppl 4):D33-D44.
• [6]Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M: Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med 2010, 7:e1000256.
• [7]Henderson DA: Universal influenza vaccination: an optimal goal–but how and when? Biosecur Bioterror 2010, 8:219-221.
• [8]Lee BY, Mehrotra A, Burns RM, Harris KM: Alternative vaccination locations: who uses them and can they increase flu vaccination rates? Vaccine 2009, 27:4252-4256.
• [9]Bain KT, Cullison MA: Deficiencies in immunization education and training in pharmacy schools: a call to action. Am J Pharm Educ 2009, 73:110.
• [10]National Vaccine Advisory Committee: A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011. Public Health Rep 2012, 127(Suppl 1):1-42.
• [11]Seasonal Flu Information for Businesses & Employees. http://www.cdc.gov/flu/business/ webcite
• [12]Prosser LA, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Messonnier ML, Lieu TA: Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. PharmacoEconomics 2008, 26:163-178.
• [13]Lee BY, Bailey RR, Wiringa AE, Afriyie A, Wateska AR, Smith KJ, Zimmerman RK: Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine 2010, 28:5952-5959.
• [14]American Academy of Actuaries: The roles of the actuary in the selection and application of actuarial models. 2006.
• [15]DeNavas-Walt C, Proctor BD, Smith JC: Income, Poverty, and Health Insurance Coverage in the United States. U.S. Government Printing Office, U.S. Census Bureau ed. Washington, DC; 2010.
• [16]Setse RW, Euler GL, Gonzalez-Feliciano AG, Bryan LN, Furlow C, Weinbaum CM, Singleton JA: Influenza vaccination coverage - United States, 2000–2010. MMWR Surveill Summ 2011, 60(Suppl):38-41.
• [17]Health Care Cost Trends. http://www.hewittassociates.com/_MetaBasicCMAssetCache_/Assets/Articles/2010/Health_Care_Cost_Trends_Nov_2010.pdf webcite
• [18]Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA: Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 2006, 12:1548-1558.
• [19]Crowe S, Utley M, Walker G, Grove P, Pagel C: A model to evaluate mass vaccination against pneumococcus as a countermeasure against pandemic influenza. Vaccine 2011, 29:5065-5077.
• [20]Das D, Metzger K, Heffernan R, Balter S, Weiss D, Mostashari F: Monitoring over-the-counter medication sales for early detection of disease outbreaks–New York City. MMWR Morb Mortal Wkly Rep 2005, 54(Suppl):41-46.
• [21]Adult Immunization. http://www.cdc.gov/workplacehealthpromotion/evaluation/topics/immunization.html#1 webcite
• [22]Loeppke R, Taitel M, Haufle V, Parry T, Kessler RC, Jinnett K: Health and productivity as a business strategy: a multiemployer study. J OccupEnvironMed 2009, 51:411-428.
• [23]Nichol KL: Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001, 161:749-759.
• [24]Place of Influenza Vaccination Among Adults --- United States, 2010--11 Influenza Season. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6023a3.htm?s_cid=mm6023a3_e&source=govdelivery webcite
• [25]Lee BY, Brown ST, Cooley PC, Zimmerman RK, Wheaton WD, Zimmer SM, Grefenstette JJ, Assi TM, Furphy TJ, Wagener DK, Burke DS: A computer simulation of employee vaccination to mitigate an influenza epidemic. Am J Prev Med 2010, 38:247-257.
• [26]Bowen JD, Goetzel RZ, Lenhart G, Ozminkowski RJ, Babamoto KS, Portale JD: Using a personal health care cost calculator to estimate future expenditures based on individual health risks. J Occup Environ Med 2009, 51:449-455.
• [27]Rothberg MB, Rose DN: Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005, 118:68-77.
• [28]Akazawa M, Sindelar JL, Paltiel AD: Economic costs of influenza-related work absenteeism. Value Health 2003, 6:107-115.
• [29]Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ: Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006, 31:72-79.
• [30]Brennan A, Chick SE, Davies R: A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006, 15:1295-1310.
• [31]Garattini L, Koleva D: Influenza vaccine for healthy adult workers: an issue for health authorities or employers? Health Policy 2011, 102:89-95.
• [32]Strikas RA, Wallace GS, Myers MG: Influenza pandemic preparedness action plan for the United States: 2002 update. Clin Infect Dis 2002, 35:590-596.